Lithium Ascorbate May Support Weight Loss Within the Depression-Obesity Feedback Loop

Depression and obesity frequently coexist and may reinforce one another through biological, behavioral, and psychosocial mechanisms, complicating both mood management and weight reduction. This paper reviews the depression–obesity feedback loop, current approaches to major depressive disorder with comorbid obesity, the use of lithium in treatment-resistant depression, and emerging evidence on lithium ascorbate, with particular attention to a weight-loss program using NORMOTIM®, a lithium ascorbate formulation. The weight-management study was conducted at the Doctor Bormental center and included 132 participants, of whom 92 (69.7%) showed signs of depression on the Beck Depression Inventory. Participants with depressive symptoms were assigned to two equal groups: a NORMOTIM group and a control group. The intervention lasted three months, with assessments of body weight and self-reported condition at one, two, and three months; complete data across all checkpoints were available for 55 participants and were included in the analysis. According to the study report, use of NORMOTIM alongside the weight-loss program increased program effectiveness by 38% in participants with emotional instability or depressive symptoms. Participant feedback also indicated stabilization of emotional background, with the reported mood-stabilizing effect emerging during weeks 2–3 and persisting throughout administration. No adverse effects or complaints were reported during the study. These findings are considered alongside broader evidence showing that conventional lithium is an established augmentation strategy for treatment-resistant depression, while concerns about lithium-associated weight gain may be greater than supported by recent meta-analytic evidence. Preclinical studies further suggest that lithium salts may differ in weight-related, pharmacological, and toxicological profiles, and that lithium ascorbate demonstrates antidepressant-like and stress-attenuating activity with a generally favorable safety profile at lower tested doses. Taken together, the available evidence supports further controlled clinical investigation of lithium ascorbate as a potential adjunct in patients with depressive symptoms undergoing structured weight-management interventions.